nodes	percent_of_prediction	percent_of_DWPC	metapath
Dronedarone—ABCB1—ovarian cancer	0.308	1	CbGaD
Dronedarone—ABCB1—Topotecan—ovarian cancer	0.0366	0.184	CbGbCtD
Dronedarone—ABCB1—Vinorelbine—ovarian cancer	0.0258	0.13	CbGbCtD
Dronedarone—CYP2D6—Vinorelbine—ovarian cancer	0.0243	0.122	CbGbCtD
Dronedarone—CYP3A4—Topotecan—ovarian cancer	0.0219	0.11	CbGbCtD
Dronedarone—ABCB1—Paclitaxel—ovarian cancer	0.0181	0.0912	CbGbCtD
Dronedarone—CYP3A4—Vinorelbine—ovarian cancer	0.0154	0.0777	CbGbCtD
Dronedarone—ABCB1—Docetaxel—ovarian cancer	0.0131	0.0659	CbGbCtD
Dronedarone—Pulmonary toxicity—Melphalan—ovarian cancer	0.0124	0.0511	CcSEcCtD
Dronedarone—CYP3A4—Paclitaxel—ovarian cancer	0.0109	0.0546	CbGbCtD
Dronedarone—Pulmonary toxicity—Vinorelbine—ovarian cancer	0.0108	0.0447	CcSEcCtD
Dronedarone—ABCB1—Doxorubicin—ovarian cancer	0.00976	0.0491	CbGbCtD
Dronedarone—CYP2D6—Doxorubicin—ovarian cancer	0.0092	0.0463	CbGbCtD
Dronedarone—CYP3A4—Docetaxel—ovarian cancer	0.00784	0.0395	CbGbCtD
Dronedarone—Pulmonary fibrosis—Chlorambucil—ovarian cancer	0.00733	0.0303	CcSEcCtD
Dronedarone—Pulmonary fibrosis—Melphalan—ovarian cancer	0.00639	0.0264	CcSEcCtD
Dronedarone—HCN4—testis—ovarian cancer	0.00596	0.0446	CbGeAlD
Dronedarone—CYP3A4—Doxorubicin—ovarian cancer	0.00585	0.0294	CbGbCtD
Dronedarone—HCN3—vagina—ovarian cancer	0.0054	0.0404	CbGeAlD
Dronedarone—CACNB3—myometrium—ovarian cancer	0.00483	0.0362	CbGeAlD
Dronedarone—HCN3—testis—ovarian cancer	0.00482	0.036	CbGeAlD
Dronedarone—Interstitial lung disease—Chlorambucil—ovarian cancer	0.00456	0.0188	CcSEcCtD
Dronedarone—HCN2—testis—ovarian cancer	0.00451	0.0338	CbGeAlD
Dronedarone—Dermatitis atopic—Chlorambucil—ovarian cancer	0.00436	0.018	CcSEcCtD
Dronedarone—Interstitial lung disease—Topotecan—ovarian cancer	0.00406	0.0167	CcSEcCtD
Dronedarone—Interstitial lung disease—Melphalan—ovarian cancer	0.00397	0.0164	CcSEcCtD
Dronedarone—Dermatitis atopic—Melphalan—ovarian cancer	0.0038	0.0157	CcSEcCtD
Dronedarone—CACNB3—uterine cervix—ovarian cancer	0.00376	0.0281	CbGeAlD
Dronedarone—Pulmonary fibrosis—Paclitaxel—ovarian cancer	0.00376	0.0155	CcSEcCtD
Dronedarone—Rash erythematous—Topotecan—ovarian cancer	0.00375	0.0155	CcSEcCtD
Dronedarone—Atrial flutter—Docetaxel—ovarian cancer	0.00368	0.0152	CcSEcCtD
Dronedarone—CACNB3—decidua—ovarian cancer	0.00358	0.0268	CbGeAlD
Dronedarone—CACNB3—endometrium—ovarian cancer	0.0034	0.0255	CbGeAlD
Dronedarone—CACNB4—vagina—ovarian cancer	0.00333	0.0249	CbGeAlD
Dronedarone—Pulmonary fibrosis—Docetaxel—ovarian cancer	0.00318	0.0131	CcSEcCtD
Dronedarone—CACNB3—uterus—ovarian cancer	0.00313	0.0235	CbGeAlD
Dronedarone—CACNB4—testis—ovarian cancer	0.00297	0.0222	CbGeAlD
Dronedarone—KCNK2—vagina—ovarian cancer	0.00295	0.0221	CbGeAlD
Dronedarone—Vasculitis—Melphalan—ovarian cancer	0.00288	0.0119	CcSEcCtD
Dronedarone—CACNB3—female reproductive system—ovarian cancer	0.00282	0.0211	CbGeAlD
Dronedarone—Fatigue—Altretamine—ovarian cancer	0.00279	0.0115	CcSEcCtD
Dronedarone—CACNB1—female gonad—ovarian cancer	0.00267	0.02	CbGeAlD
Dronedarone—KCNK2—testis—ovarian cancer	0.00263	0.0197	CbGeAlD
Dronedarone—CACNA1C—myometrium—ovarian cancer	0.00262	0.0196	CbGeAlD
Dronedarone—Hypomagnesaemia—Paclitaxel—ovarian cancer	0.0026	0.0107	CcSEcCtD
Dronedarone—CACNB3—female gonad—ovarian cancer	0.00256	0.0192	CbGeAlD
Dronedarone—CACNB3—vagina—ovarian cancer	0.00255	0.0191	CbGeAlD
Dronedarone—CACNB1—testis—ovarian cancer	0.00237	0.0177	CbGeAlD
Dronedarone—Interstitial lung disease—Paclitaxel—ovarian cancer	0.00233	0.00964	CcSEcCtD
Dronedarone—Asthenia—Altretamine—ovarian cancer	0.00232	0.00959	CcSEcCtD
Dronedarone—CACNB3—testis—ovarian cancer	0.00227	0.017	CbGeAlD
Dronedarone—Dermatitis atopic—Paclitaxel—ovarian cancer	0.00223	0.00922	CcSEcCtD
Dronedarone—ADRA1D—epithelium—ovarian cancer	0.00221	0.0165	CbGeAlD
Dronedarone—CACNA1D—uterine cervix—ovarian cancer	0.00221	0.0165	CbGeAlD
Dronedarone—Rash erythematous—Paclitaxel—ovarian cancer	0.00216	0.00891	CcSEcCtD
Dronedarone—Vomiting—Altretamine—ovarian cancer	0.00206	0.0085	CcSEcCtD
Dronedarone—Interstitial lung disease—Docetaxel—ovarian cancer	0.00198	0.00817	CcSEcCtD
Dronedarone—CACNA1C—decidua—ovarian cancer	0.00194	0.0145	CbGeAlD
Dronedarone—Nausea—Altretamine—ovarian cancer	0.00192	0.00794	CcSEcCtD
Dronedarone—KCNK2—lymph node—ovarian cancer	0.00191	0.0143	CbGeAlD
Dronedarone—Dermatitis atopic—Docetaxel—ovarian cancer	0.00189	0.00781	CcSEcCtD
Dronedarone—Rash erythematous—Docetaxel—ovarian cancer	0.00183	0.00755	CcSEcCtD
Dronedarone—Cardiac failure—Vinorelbine—ovarian cancer	0.00183	0.00754	CcSEcCtD
Dronedarone—Pneumonia—Chlorambucil—ovarian cancer	0.00181	0.00749	CcSEcCtD
Dronedarone—Ageusia—Docetaxel—ovarian cancer	0.00173	0.00714	CcSEcCtD
Dronedarone—CACNB1—lymph node—ovarian cancer	0.00172	0.0129	CbGeAlD
Dronedarone—CACNB2—vagina—ovarian cancer	0.00171	0.0128	CbGeAlD
Dronedarone—Blood creatinine increased—Vinorelbine—ovarian cancer	0.00167	0.0069	CcSEcCtD
Dronedarone—CACNB3—lymph node—ovarian cancer	0.00165	0.0123	CbGeAlD
Dronedarone—ADRA1D—female reproductive system—ovarian cancer	0.00164	0.0123	CbGeAlD
Dronedarone—Pneumonia—Topotecan—ovarian cancer	0.00162	0.00667	CcSEcCtD
Dronedarone—KCNH2—myometrium—ovarian cancer	0.00156	0.0117	CbGeAlD
Dronedarone—ADRA2C—myometrium—ovarian cancer	0.00154	0.0115	CbGeAlD
Dronedarone—CACNB2—testis—ovarian cancer	0.00153	0.0114	CbGeAlD
Dronedarone—CACNA1C—female reproductive system—ovarian cancer	0.00153	0.0114	CbGeAlD
Dronedarone—Hepatobiliary disease—Topotecan—ovarian cancer	0.00152	0.00627	CcSEcCtD
Dronedarone—Hepatobiliary disease—Melphalan—ovarian cancer	0.00149	0.00614	CcSEcCtD
Dronedarone—Hypomagnesaemia—Epirubicin—ovarian cancer	0.00149	0.00614	CcSEcCtD
Dronedarone—Pneumonia—Vinorelbine—ovarian cancer	0.00138	0.00571	CcSEcCtD
Dronedarone—CACNA1C—vagina—ovarian cancer	0.00138	0.0103	CbGeAlD
Dronedarone—Hypomagnesaemia—Doxorubicin—ovarian cancer	0.00138	0.00568	CcSEcCtD
Dronedarone—CACNA1D—testis—ovarian cancer	0.00134	0.00999	CbGeAlD
Dronedarone—Cardiac failure congestive—Paclitaxel—ovarian cancer	0.00132	0.00546	CcSEcCtD
Dronedarone—Angiopathy—Topotecan—ovarian cancer	0.00131	0.0054	CcSEcCtD
Dronedarone—Immune system disorder—Topotecan—ovarian cancer	0.0013	0.00538	CcSEcCtD
Dronedarone—Mediastinal disorder—Topotecan—ovarian cancer	0.0013	0.00537	CcSEcCtD
Dronedarone—Hepatobiliary disease—Vinorelbine—ovarian cancer	0.0013	0.00537	CcSEcCtD
Dronedarone—Angioedema—Chlorambucil—ovarian cancer	0.00129	0.00532	CcSEcCtD
Dronedarone—Dermatitis atopic—Epirubicin—ovarian cancer	0.00128	0.00527	CcSEcCtD
Dronedarone—Immune system disorder—Melphalan—ovarian cancer	0.00128	0.00527	CcSEcCtD
Dronedarone—Mediastinal disorder—Melphalan—ovarian cancer	0.00127	0.00525	CcSEcCtD
Dronedarone—ADRA1A—epithelium—ovarian cancer	0.00127	0.00949	CbGeAlD
Dronedarone—Rash erythematous—Epirubicin—ovarian cancer	0.00123	0.00509	CcSEcCtD
Dronedarone—CACNA1C—testis—ovarian cancer	0.00123	0.00923	CbGeAlD
Dronedarone—ADRA2A—myometrium—ovarian cancer	0.00123	0.0092	CbGeAlD
Dronedarone—Cardiac failure—Paclitaxel—ovarian cancer	0.00123	0.00507	CcSEcCtD
Dronedarone—KCNH2—uterine cervix—ovarian cancer	0.00121	0.00909	CbGeAlD
Dronedarone—ADRA2C—uterine cervix—ovarian cancer	0.0012	0.00897	CbGeAlD
Dronedarone—ADRB1—female reproductive system—ovarian cancer	0.00119	0.00892	CbGeAlD
Dronedarone—Dermatitis atopic—Doxorubicin—ovarian cancer	0.00118	0.00488	CcSEcCtD
Dronedarone—Ageusia—Epirubicin—ovarian cancer	0.00117	0.00481	CcSEcCtD
Dronedarone—Angioedema—Topotecan—ovarian cancer	0.00115	0.00474	CcSEcCtD
Dronedarone—Cardiac disorder—Vinorelbine—ovarian cancer	0.00114	0.00473	CcSEcCtD
Dronedarone—ADRA2C—decidua—ovarian cancer	0.00114	0.00855	CbGeAlD
Dronedarone—Rash erythematous—Doxorubicin—ovarian cancer	0.00114	0.00471	CcSEcCtD
Dronedarone—Blood creatinine increased—Paclitaxel—ovarian cancer	0.00112	0.00464	CcSEcCtD
Dronedarone—Liver injury—Epirubicin—ovarian cancer	0.00112	0.00463	CcSEcCtD
Dronedarone—Cardiac failure congestive—Docetaxel—ovarian cancer	0.00112	0.00463	CcSEcCtD
Dronedarone—Angiopathy—Vinorelbine—ovarian cancer	0.00112	0.00462	CcSEcCtD
Dronedarone—Immune system disorder—Vinorelbine—ovarian cancer	0.00111	0.0046	CcSEcCtD
Dronedarone—Mediastinal disorder—Vinorelbine—ovarian cancer	0.00111	0.00459	CcSEcCtD
Dronedarone—CACNB2—lymph node—ovarian cancer	0.00111	0.00829	CbGeAlD
Dronedarone—KCNH2—endometrium—ovarian cancer	0.0011	0.00822	CbGeAlD
Dronedarone—Hypokalaemia—Paclitaxel—ovarian cancer	0.00109	0.00451	CcSEcCtD
Dronedarone—ADRA2C—endometrium—ovarian cancer	0.00108	0.00811	CbGeAlD
Dronedarone—Ageusia—Doxorubicin—ovarian cancer	0.00108	0.00445	CcSEcCtD
Dronedarone—Erythema—Vinorelbine—ovarian cancer	0.00107	0.00443	CcSEcCtD
Dronedarone—Unspecified disorder of skin and subcutaneous tissue—Topotecan—ovarian cancer	0.00106	0.00438	CcSEcCtD
Dronedarone—Cardiac failure—Docetaxel—ovarian cancer	0.00104	0.0043	CcSEcCtD
Dronedarone—Unspecified disorder of skin and subcutaneous tissue—Melphalan—ovarian cancer	0.00104	0.00429	CcSEcCtD
Dronedarone—Liver injury—Doxorubicin—ovarian cancer	0.00104	0.00429	CcSEcCtD
Dronedarone—Anaphylactic shock—Topotecan—ovarian cancer	0.00102	0.00423	CcSEcCtD
Dronedarone—Dyspepsia—Chlorambucil—ovarian cancer	0.00101	0.00418	CcSEcCtD
Dronedarone—KCNH2—uterus—ovarian cancer	0.00101	0.00758	CbGeAlD
Dronedarone—Nervous system disorder—Topotecan—ovarian cancer	0.001	0.00415	CcSEcCtD
Dronedarone—Anaphylactic shock—Melphalan—ovarian cancer	0.001	0.00414	CcSEcCtD
Dronedarone—ADRA2C—uterus—ovarian cancer	0.000999	0.00748	CbGeAlD
Dronedarone—Skin disorder—Topotecan—ovarian cancer	0.000995	0.00411	CcSEcCtD
Dronedarone—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.000993	0.0041	CcSEcCtD
Dronedarone—Fatigue—Chlorambucil—ovarian cancer	0.000992	0.0041	CcSEcCtD
Dronedarone—Angioedema—Vinorelbine—ovarian cancer	0.000981	0.00405	CcSEcCtD
Dronedarone—Skin disorder—Melphalan—ovarian cancer	0.000974	0.00402	CcSEcCtD
Dronedarone—CACNA1D—lymph node—ovarian cancer	0.000968	0.00724	CbGeAlD
Dronedarone—ADRA2A—uterine cervix—ovarian cancer	0.000956	0.00716	CbGeAlD
Dronedarone—ALB—testis—ovarian cancer	0.000956	0.00716	CbGeAlD
Dronedarone—Photosensitivity reaction—Paclitaxel—ovarian cancer	0.000946	0.00391	CcSEcCtD
Dronedarone—Gastrointestinal pain—Chlorambucil—ovarian cancer	0.000941	0.00389	CcSEcCtD
Dronedarone—Pneumonia—Paclitaxel—ovarian cancer	0.000929	0.00384	CcSEcCtD
Dronedarone—ADRA2A—decidua—ovarian cancer	0.000911	0.00682	CbGeAlD
Dronedarone—KCNH2—female reproductive system—ovarian cancer	0.00091	0.00681	CbGeAlD
Dronedarone—Abdominal pain—Chlorambucil—ovarian cancer	0.00091	0.00376	CcSEcCtD
Dronedarone—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.000908	0.00375	CcSEcCtD
Dronedarone—Dyspepsia—Topotecan—ovarian cancer	0.000902	0.00372	CcSEcCtD
Dronedarone—CACNA1C—lymph node—ovarian cancer	0.000894	0.00669	CbGeAlD
Dronedarone—Gastrointestinal disorder—Topotecan—ovarian cancer	0.000884	0.00365	CcSEcCtD
Dronedarone—Fatigue—Topotecan—ovarian cancer	0.000883	0.00365	CcSEcCtD
Dronedarone—Dyspepsia—Melphalan—ovarian cancer	0.000883	0.00365	CcSEcCtD
Dronedarone—Anaphylactic shock—Vinorelbine—ovarian cancer	0.000876	0.00362	CcSEcCtD
Dronedarone—Hepatobiliary disease—Paclitaxel—ovarian cancer	0.000874	0.00361	CcSEcCtD
Dronedarone—Gastrointestinal disorder—Melphalan—ovarian cancer	0.000866	0.00358	CcSEcCtD
Dronedarone—ADRA2A—endometrium—ovarian cancer	0.000865	0.00647	CbGeAlD
Dronedarone—Fatigue—Melphalan—ovarian cancer	0.000865	0.00357	CcSEcCtD
Dronedarone—Nervous system disorder—Vinorelbine—ovarian cancer	0.000859	0.00355	CcSEcCtD
Dronedarone—KCNH2—bone marrow—ovarian cancer	0.000859	0.00643	CbGeAlD
Dronedarone—Skin disorder—Vinorelbine—ovarian cancer	0.000851	0.00351	CcSEcCtD
Dronedarone—Bradycardia—Paclitaxel—ovarian cancer	0.000845	0.00349	CcSEcCtD
Dronedarone—Gastrointestinal pain—Topotecan—ovarian cancer	0.000838	0.00346	CcSEcCtD
Dronedarone—KCNH2—female gonad—ovarian cancer	0.000828	0.0062	CbGeAlD
Dronedarone—Asthenia—Chlorambucil—ovarian cancer	0.000826	0.00341	CcSEcCtD
Dronedarone—KCNH2—vagina—ovarian cancer	0.000823	0.00616	CbGeAlD
Dronedarone—ADRA2C—female gonad—ovarian cancer	0.000817	0.00612	CbGeAlD
Dronedarone—Pruritus—Chlorambucil—ovarian cancer	0.000814	0.00336	CcSEcCtD
Dronedarone—ADRA2C—vagina—ovarian cancer	0.000812	0.00608	CbGeAlD
Dronedarone—Abdominal pain—Topotecan—ovarian cancer	0.00081	0.00334	CcSEcCtD
Dronedarone—ADRA2A—gonad—ovarian cancer	0.000802	0.006	CbGeAlD
Dronedarone—ADRA2A—uterus—ovarian cancer	0.000797	0.00597	CbGeAlD
Dronedarone—Pneumonia—Docetaxel—ovarian cancer	0.000788	0.00325	CcSEcCtD
Dronedarone—Diarrhoea—Chlorambucil—ovarian cancer	0.000787	0.00325	CcSEcCtD
Dronedarone—Cardiac disorder—Paclitaxel—ovarian cancer	0.00077	0.00318	CcSEcCtD
Dronedarone—Eczema—Epirubicin—ovarian cancer	0.000763	0.00315	CcSEcCtD
Dronedarone—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000756	0.00312	CcSEcCtD
Dronedarone—Cardiac failure congestive—Epirubicin—ovarian cancer	0.000756	0.00312	CcSEcCtD
Dronedarone—Fatigue—Vinorelbine—ovarian cancer	0.000755	0.00312	CcSEcCtD
Dronedarone—Angiopathy—Paclitaxel—ovarian cancer	0.000753	0.00311	CcSEcCtD
Dronedarone—Immune system disorder—Paclitaxel—ovarian cancer	0.000749	0.00309	CcSEcCtD
Dronedarone—Mediastinal disorder—Paclitaxel—ovarian cancer	0.000748	0.00309	CcSEcCtD
Dronedarone—Hepatobiliary disease—Docetaxel—ovarian cancer	0.000741	0.00306	CcSEcCtD
Dronedarone—Asthenia—Topotecan—ovarian cancer	0.000735	0.00303	CcSEcCtD
Dronedarone—KCNH2—testis—ovarian cancer	0.000735	0.0055	CbGeAlD
Dronedarone—Vomiting—Chlorambucil—ovarian cancer	0.000732	0.00302	CcSEcCtD
Dronedarone—ADRA2C—testis—ovarian cancer	0.000725	0.00542	CbGeAlD
Dronedarone—Pruritus—Topotecan—ovarian cancer	0.000725	0.00299	CcSEcCtD
Dronedarone—Erythema—Paclitaxel—ovarian cancer	0.000722	0.00298	CcSEcCtD
Dronedarone—Asthenia—Melphalan—ovarian cancer	0.00072	0.00297	CcSEcCtD
Dronedarone—ADRA2A—female reproductive system—ovarian cancer	0.000717	0.00536	CbGeAlD
Dronedarone—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000717	0.00296	CcSEcCtD
Dronedarone—Pruritus—Melphalan—ovarian cancer	0.00071	0.00293	CcSEcCtD
Dronedarone—Dysgeusia—Paclitaxel—ovarian cancer	0.000707	0.00292	CcSEcCtD
Dronedarone—Eczema—Doxorubicin—ovarian cancer	0.000706	0.00291	CcSEcCtD
Dronedarone—Cardiac failure—Epirubicin—ovarian cancer	0.000702	0.0029	CcSEcCtD
Dronedarone—Diarrhoea—Topotecan—ovarian cancer	0.000701	0.00289	CcSEcCtD
Dronedarone—Cardiac failure congestive—Doxorubicin—ovarian cancer	0.000699	0.00289	CcSEcCtD
Dronedarone—ALB—lymph node—ovarian cancer	0.000693	0.00519	CbGeAlD
Dronedarone—Abdominal pain—Vinorelbine—ovarian cancer	0.000693	0.00286	CcSEcCtD
Dronedarone—Diarrhoea—Melphalan—ovarian cancer	0.000686	0.00283	CcSEcCtD
Dronedarone—ABCB1—myometrium—ovarian cancer	0.000685	0.00512	CbGeAlD
Dronedarone—Nausea—Chlorambucil—ovarian cancer	0.000683	0.00282	CcSEcCtD
Dronedarone—Angioedema—Paclitaxel—ovarian cancer	0.00066	0.00272	CcSEcCtD
Dronedarone—ABCB1—embryo—ovarian cancer	0.000659	0.00493	CbGeAlD
Dronedarone—Cardiac disorder—Docetaxel—ovarian cancer	0.000653	0.00269	CcSEcCtD
Dronedarone—ADRA2A—female gonad—ovarian cancer	0.000652	0.00488	CbGeAlD
Dronedarone—Vomiting—Topotecan—ovarian cancer	0.000651	0.00269	CcSEcCtD
Dronedarone—Cardiac failure—Doxorubicin—ovarian cancer	0.00065	0.00268	CcSEcCtD
Dronedarone—ADRA2A—vagina—ovarian cancer	0.000648	0.00485	CbGeAlD
Dronedarone—Rash—Topotecan—ovarian cancer	0.000646	0.00267	CcSEcCtD
Dronedarone—Dermatitis—Topotecan—ovarian cancer	0.000645	0.00266	CcSEcCtD
Dronedarone—Blood creatinine increased—Epirubicin—ovarian cancer	0.000642	0.00265	CcSEcCtD
Dronedarone—Angiopathy—Docetaxel—ovarian cancer	0.000638	0.00263	CcSEcCtD
Dronedarone—Vomiting—Melphalan—ovarian cancer	0.000638	0.00263	CcSEcCtD
Dronedarone—Immune system disorder—Docetaxel—ovarian cancer	0.000635	0.00262	CcSEcCtD
Dronedarone—Mediastinal disorder—Docetaxel—ovarian cancer	0.000634	0.00262	CcSEcCtD
Dronedarone—Rash—Melphalan—ovarian cancer	0.000632	0.00261	CcSEcCtD
Dronedarone—Dermatitis—Melphalan—ovarian cancer	0.000632	0.00261	CcSEcCtD
Dronedarone—Asthenia—Vinorelbine—ovarian cancer	0.000629	0.0026	CcSEcCtD
Dronedarone—Hypokalaemia—Epirubicin—ovarian cancer	0.000624	0.00258	CcSEcCtD
Dronedarone—Pruritus—Vinorelbine—ovarian cancer	0.00062	0.00256	CcSEcCtD
Dronedarone—Erythema—Docetaxel—ovarian cancer	0.000612	0.00253	CcSEcCtD
Dronedarone—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000611	0.00252	CcSEcCtD
Dronedarone—Nausea—Topotecan—ovarian cancer	0.000608	0.00251	CcSEcCtD
Dronedarone—Diarrhoea—Vinorelbine—ovarian cancer	0.0006	0.00248	CcSEcCtD
Dronedarone—Dysgeusia—Docetaxel—ovarian cancer	0.000599	0.00248	CcSEcCtD
Dronedarone—Nausea—Melphalan—ovarian cancer	0.000596	0.00246	CcSEcCtD
Dronedarone—Blood creatinine increased—Doxorubicin—ovarian cancer	0.000594	0.00245	CcSEcCtD
Dronedarone—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000589	0.00243	CcSEcCtD
Dronedarone—ADRA2A—testis—ovarian cancer	0.000578	0.00433	CbGeAlD
Dronedarone—Nervous system disorder—Paclitaxel—ovarian cancer	0.000578	0.00239	CcSEcCtD
Dronedarone—Hypokalaemia—Doxorubicin—ovarian cancer	0.000577	0.00238	CcSEcCtD
Dronedarone—Skin disorder—Paclitaxel—ovarian cancer	0.000572	0.00236	CcSEcCtD
Dronedarone—CYP3A4—female reproductive system—ovarian cancer	0.000564	0.00422	CbGeAlD
Dronedarone—Vomiting—Vinorelbine—ovarian cancer	0.000557	0.0023	CcSEcCtD
Dronedarone—CYP2D6—female reproductive system—ovarian cancer	0.000555	0.00415	CbGeAlD
Dronedarone—Rash—Vinorelbine—ovarian cancer	0.000552	0.00228	CcSEcCtD
Dronedarone—Dermatitis—Vinorelbine—ovarian cancer	0.000552	0.00228	CcSEcCtD
Dronedarone—Photosensitivity reaction—Epirubicin—ovarian cancer	0.000541	0.00223	CcSEcCtD
Dronedarone—ABCB1—epithelium—ovarian cancer	0.000537	0.00402	CbGeAlD
Dronedarone—ABCB1—uterine cervix—ovarian cancer	0.000533	0.00399	CbGeAlD
Dronedarone—KCNH2—lymph node—ovarian cancer	0.000532	0.00398	CbGeAlD
Dronedarone—Pneumonia—Epirubicin—ovarian cancer	0.000531	0.00219	CcSEcCtD
Dronedarone—ADRA2C—lymph node—ovarian cancer	0.000525	0.00393	CbGeAlD
Dronedarone—Nausea—Vinorelbine—ovarian cancer	0.00052	0.00215	CcSEcCtD
Dronedarone—Dyspepsia—Paclitaxel—ovarian cancer	0.000519	0.00214	CcSEcCtD
Dronedarone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000518	0.00214	CcSEcCtD
Dronedarone—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000509	0.0021	CcSEcCtD
Dronedarone—Fatigue—Paclitaxel—ovarian cancer	0.000508	0.0021	CcSEcCtD
Dronedarone—ABCB1—decidua—ovarian cancer	0.000508	0.0038	CbGeAlD
Dronedarone—CYP2D6—female gonad—ovarian cancer	0.000505	0.00378	CbGeAlD
Dronedarone—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.0005	0.00207	CcSEcCtD
Dronedarone—Hepatobiliary disease—Epirubicin—ovarian cancer	0.0005	0.00206	CcSEcCtD
Dronedarone—Anaphylactic shock—Docetaxel—ovarian cancer	0.0005	0.00206	CcSEcCtD
Dronedarone—Pneumonia—Doxorubicin—ovarian cancer	0.000492	0.00203	CcSEcCtD
Dronedarone—Nervous system disorder—Docetaxel—ovarian cancer	0.00049	0.00202	CcSEcCtD
Dronedarone—Skin disorder—Docetaxel—ovarian cancer	0.000485	0.002	CcSEcCtD
Dronedarone—Bradycardia—Epirubicin—ovarian cancer	0.000483	0.00199	CcSEcCtD
Dronedarone—ABCB1—endometrium—ovarian cancer	0.000482	0.00361	CbGeAlD
Dronedarone—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000482	0.00199	CcSEcCtD
Dronedarone—Abdominal pain—Paclitaxel—ovarian cancer	0.000466	0.00192	CcSEcCtD
Dronedarone—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000462	0.00191	CcSEcCtD
Dronedarone—CYP2D6—testis—ovarian cancer	0.000448	0.00335	CbGeAlD
Dronedarone—ABCB1—gonad—ovarian cancer	0.000447	0.00335	CbGeAlD
Dronedarone—Bradycardia—Doxorubicin—ovarian cancer	0.000447	0.00184	CcSEcCtD
Dronedarone—ABCB1—uterus—ovarian cancer	0.000444	0.00332	CbGeAlD
Dronedarone—Cardiac disorder—Epirubicin—ovarian cancer	0.00044	0.00182	CcSEcCtD
Dronedarone—Dyspepsia—Docetaxel—ovarian cancer	0.00044	0.00182	CcSEcCtD
Dronedarone—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000431	0.00178	CcSEcCtD
Dronedarone—Fatigue—Docetaxel—ovarian cancer	0.000431	0.00178	CcSEcCtD
Dronedarone—Angiopathy—Epirubicin—ovarian cancer	0.00043	0.00178	CcSEcCtD
Dronedarone—Immune system disorder—Epirubicin—ovarian cancer	0.000428	0.00177	CcSEcCtD
Dronedarone—Mediastinal disorder—Epirubicin—ovarian cancer	0.000427	0.00176	CcSEcCtD
Dronedarone—Asthenia—Paclitaxel—ovarian cancer	0.000423	0.00175	CcSEcCtD
Dronedarone—ADRA2A—lymph node—ovarian cancer	0.000419	0.00314	CbGeAlD
Dronedarone—Pruritus—Paclitaxel—ovarian cancer	0.000417	0.00172	CcSEcCtD
Dronedarone—Erythema—Epirubicin—ovarian cancer	0.000413	0.0017	CcSEcCtD
Dronedarone—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000408	0.00169	CcSEcCtD
Dronedarone—Cardiac disorder—Doxorubicin—ovarian cancer	0.000407	0.00168	CcSEcCtD
Dronedarone—Dysgeusia—Epirubicin—ovarian cancer	0.000404	0.00167	CcSEcCtD
Dronedarone—Diarrhoea—Paclitaxel—ovarian cancer	0.000403	0.00167	CcSEcCtD
Dronedarone—ABCB1—female reproductive system—ovarian cancer	0.000399	0.00299	CbGeAlD
Dronedarone—Angiopathy—Doxorubicin—ovarian cancer	0.000398	0.00164	CcSEcCtD
Dronedarone—Immune system disorder—Doxorubicin—ovarian cancer	0.000396	0.00164	CcSEcCtD
Dronedarone—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000395	0.00163	CcSEcCtD
Dronedarone—Abdominal pain—Docetaxel—ovarian cancer	0.000395	0.00163	CcSEcCtD
Dronedarone—Erythema—Doxorubicin—ovarian cancer	0.000382	0.00158	CcSEcCtD
Dronedarone—ABCB1—bone marrow—ovarian cancer	0.000377	0.00282	CbGeAlD
Dronedarone—Vomiting—Paclitaxel—ovarian cancer	0.000375	0.00155	CcSEcCtD
Dronedarone—Dysgeusia—Doxorubicin—ovarian cancer	0.000374	0.00154	CcSEcCtD
Dronedarone—Rash—Paclitaxel—ovarian cancer	0.000372	0.00153	CcSEcCtD
Dronedarone—Dermatitis—Paclitaxel—ovarian cancer	0.000371	0.00153	CcSEcCtD
Dronedarone—ABCB1—female gonad—ovarian cancer	0.000363	0.00272	CbGeAlD
Dronedarone—ABCB1—vagina—ovarian cancer	0.000361	0.0027	CbGeAlD
Dronedarone—Asthenia—Docetaxel—ovarian cancer	0.000358	0.00148	CcSEcCtD
Dronedarone—Pruritus—Docetaxel—ovarian cancer	0.000353	0.00146	CcSEcCtD
Dronedarone—Nausea—Paclitaxel—ovarian cancer	0.00035	0.00145	CcSEcCtD
Dronedarone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000349	0.00144	CcSEcCtD
Dronedarone—Diarrhoea—Docetaxel—ovarian cancer	0.000342	0.00141	CcSEcCtD
Dronedarone—Anaphylactic shock—Epirubicin—ovarian cancer	0.000337	0.00139	CcSEcCtD
Dronedarone—Nervous system disorder—Epirubicin—ovarian cancer	0.00033	0.00136	CcSEcCtD
Dronedarone—Skin disorder—Epirubicin—ovarian cancer	0.000327	0.00135	CcSEcCtD
Dronedarone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000323	0.00133	CcSEcCtD
Dronedarone—ABCB1—testis—ovarian cancer	0.000322	0.00241	CbGeAlD
Dronedarone—Vomiting—Docetaxel—ovarian cancer	0.000318	0.00131	CcSEcCtD
Dronedarone—Rash—Docetaxel—ovarian cancer	0.000315	0.0013	CcSEcCtD
Dronedarone—Dermatitis—Docetaxel—ovarian cancer	0.000315	0.0013	CcSEcCtD
Dronedarone—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000312	0.00129	CcSEcCtD
Dronedarone—Nervous system disorder—Doxorubicin—ovarian cancer	0.000306	0.00126	CcSEcCtD
Dronedarone—Skin disorder—Doxorubicin—ovarian cancer	0.000303	0.00125	CcSEcCtD
Dronedarone—Nausea—Docetaxel—ovarian cancer	0.000297	0.00123	CcSEcCtD
Dronedarone—Dyspepsia—Epirubicin—ovarian cancer	0.000297	0.00122	CcSEcCtD
Dronedarone—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000291	0.0012	CcSEcCtD
Dronedarone—Fatigue—Epirubicin—ovarian cancer	0.000291	0.0012	CcSEcCtD
Dronedarone—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000276	0.00114	CcSEcCtD
Dronedarone—Dyspepsia—Doxorubicin—ovarian cancer	0.000274	0.00113	CcSEcCtD
Dronedarone—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000269	0.00111	CcSEcCtD
Dronedarone—Fatigue—Doxorubicin—ovarian cancer	0.000269	0.00111	CcSEcCtD
Dronedarone—Abdominal pain—Epirubicin—ovarian cancer	0.000266	0.0011	CcSEcCtD
Dronedarone—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000255	0.00105	CcSEcCtD
Dronedarone—Abdominal pain—Doxorubicin—ovarian cancer	0.000246	0.00102	CcSEcCtD
Dronedarone—Asthenia—Epirubicin—ovarian cancer	0.000242	0.000998	CcSEcCtD
Dronedarone—Pruritus—Epirubicin—ovarian cancer	0.000238	0.000984	CcSEcCtD
Dronedarone—ABCB1—lymph node—ovarian cancer	0.000234	0.00175	CbGeAlD
Dronedarone—Diarrhoea—Epirubicin—ovarian cancer	0.000231	0.000952	CcSEcCtD
Dronedarone—Asthenia—Doxorubicin—ovarian cancer	0.000224	0.000924	CcSEcCtD
Dronedarone—Pruritus—Doxorubicin—ovarian cancer	0.000221	0.000911	CcSEcCtD
Dronedarone—Vomiting—Epirubicin—ovarian cancer	0.000214	0.000885	CcSEcCtD
Dronedarone—Diarrhoea—Doxorubicin—ovarian cancer	0.000213	0.000881	CcSEcCtD
Dronedarone—Rash—Epirubicin—ovarian cancer	0.000212	0.000877	CcSEcCtD
Dronedarone—Dermatitis—Epirubicin—ovarian cancer	0.000212	0.000876	CcSEcCtD
Dronedarone—Nausea—Epirubicin—ovarian cancer	0.0002	0.000826	CcSEcCtD
Dronedarone—Vomiting—Doxorubicin—ovarian cancer	0.000198	0.000819	CcSEcCtD
Dronedarone—Rash—Doxorubicin—ovarian cancer	0.000197	0.000812	CcSEcCtD
Dronedarone—Dermatitis—Doxorubicin—ovarian cancer	0.000196	0.000811	CcSEcCtD
Dronedarone—Nausea—Doxorubicin—ovarian cancer	0.000185	0.000765	CcSEcCtD
Dronedarone—ADRA1D—Signaling Pathways—IL2—ovarian cancer	9.38e-06	7.99e-05	CbGpPWpGaD
Dronedarone—ADRA2B—Signaling Pathways—ERBB2—ovarian cancer	9.34e-06	7.96e-05	CbGpPWpGaD
Dronedarone—ADRA1D—Signaling by GPCR—IL6—ovarian cancer	9.33e-06	7.95e-05	CbGpPWpGaD
Dronedarone—ADRB1—Signaling Pathways—PIK3CB—ovarian cancer	9.3e-06	7.93e-05	CbGpPWpGaD
Dronedarone—ADRB1—Signaling Pathways—MTOR—ovarian cancer	9.3e-06	7.93e-05	CbGpPWpGaD
Dronedarone—ADRA2B—Signaling Pathways—MTOR—ovarian cancer	9.22e-06	7.85e-05	CbGpPWpGaD
Dronedarone—ADRA2B—Signaling Pathways—PIK3CB—ovarian cancer	9.22e-06	7.85e-05	CbGpPWpGaD
Dronedarone—ALB—Hemostasis—HRAS—ovarian cancer	9.18e-06	7.82e-05	CbGpPWpGaD
Dronedarone—ADRA1D—Signaling Pathways—CCND1—ovarian cancer	9.14e-06	7.79e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling Pathways—APC—ovarian cancer	9.13e-06	7.78e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling Pathways—PIK3CG—ovarian cancer	9.13e-06	7.78e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling by GPCR—NRAS—ovarian cancer	9.13e-06	7.78e-05	CbGpPWpGaD
Dronedarone—ADRA1D—Signaling Pathways—CTNNB1—ovarian cancer	9.05e-06	7.71e-05	CbGpPWpGaD
Dronedarone—ALB—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	9.04e-06	7.7e-05	CbGpPWpGaD
Dronedarone—ADRA1A—Signaling by GPCR—MAPK1—ovarian cancer	8.95e-06	7.63e-05	CbGpPWpGaD
Dronedarone—ADRA1A—Signaling by GPCR—EGFR—ovarian cancer	8.95e-06	7.62e-05	CbGpPWpGaD
Dronedarone—ADRB1—Signaling Pathways—CXCL8—ovarian cancer	8.94e-06	7.62e-05	CbGpPWpGaD
Dronedarone—ADRA2C—Metabolism—PTEN—ovarian cancer	8.9e-06	7.58e-05	CbGpPWpGaD
Dronedarone—ADRA2C—Signaling by GPCR—PIK3CA—ovarian cancer	8.89e-06	7.57e-05	CbGpPWpGaD
Dronedarone—ADRB1—Signaling by GPCR—HRAS—ovarian cancer	8.88e-06	7.57e-05	CbGpPWpGaD
Dronedarone—ADRA1D—Signaling Pathways—MMP9—ovarian cancer	8.88e-06	7.56e-05	CbGpPWpGaD
Dronedarone—ADRA2B—Signaling Pathways—CXCL8—ovarian cancer	8.86e-06	7.55e-05	CbGpPWpGaD
Dronedarone—ADRA1D—Signaling Pathways—PTEN—ovarian cancer	8.82e-06	7.52e-05	CbGpPWpGaD
Dronedarone—ADRA2B—Signaling by GPCR—HRAS—ovarian cancer	8.8e-06	7.5e-05	CbGpPWpGaD
Dronedarone—ADRA1B—Signaling by GPCR—PIK3CA—ovarian cancer	8.75e-06	7.45e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling by GPCR—MAPK3—ovarian cancer	8.74e-06	7.45e-05	CbGpPWpGaD
Dronedarone—ADRB1—Signaling Pathways—CDKN1B—ovarian cancer	8.73e-06	7.44e-05	CbGpPWpGaD
Dronedarone—ADRA2C—Signaling Pathways—ERBB2—ovarian cancer	8.73e-06	7.43e-05	CbGpPWpGaD
Dronedarone—ADRA2B—Signaling Pathways—CDKN1B—ovarian cancer	8.65e-06	7.37e-05	CbGpPWpGaD
Dronedarone—ADRB1—GPCR downstream signaling—AKT1—ovarian cancer	8.64e-06	7.36e-05	CbGpPWpGaD
Dronedarone—ADRA1A—Signaling Pathways—PIK3CD—ovarian cancer	8.64e-06	7.36e-05	CbGpPWpGaD
Dronedarone—CACNA1C—Metabolism—AKT1—ovarian cancer	8.62e-06	7.35e-05	CbGpPWpGaD
Dronedarone—ALB—Metabolism—PIK3CG—ovarian cancer	8.62e-06	7.34e-05	CbGpPWpGaD
Dronedarone—ADRA2C—Signaling Pathways—MTOR—ovarian cancer	8.61e-06	7.34e-05	CbGpPWpGaD
Dronedarone—ADRA2C—Signaling Pathways—PIK3CB—ovarian cancer	8.61e-06	7.34e-05	CbGpPWpGaD
Dronedarone—ADRA1D—Signaling by GPCR—AKT1—ovarian cancer	8.61e-06	7.33e-05	CbGpPWpGaD
Dronedarone—CYP3A4—Metabolism—FASN—ovarian cancer	8.6e-06	7.33e-05	CbGpPWpGaD
Dronedarone—ADRA1B—Signaling Pathways—ERBB2—ovarian cancer	8.59e-06	7.32e-05	CbGpPWpGaD
Dronedarone—ADRA2B—GPCR downstream signaling—AKT1—ovarian cancer	8.56e-06	7.29e-05	CbGpPWpGaD
Dronedarone—ADRB1—Signaling Pathways—CASP3—ovarian cancer	8.56e-06	7.29e-05	CbGpPWpGaD
Dronedarone—ADRA1A—GPCR downstream signaling—PIK3CA—ovarian cancer	8.56e-06	7.29e-05	CbGpPWpGaD
Dronedarone—ADRB1—Signaling Pathways—IL2—ovarian cancer	8.55e-06	7.28e-05	CbGpPWpGaD
Dronedarone—ADRB1—Signaling by GPCR—IL6—ovarian cancer	8.5e-06	7.24e-05	CbGpPWpGaD
Dronedarone—ADRA2B—Signaling Pathways—CASP3—ovarian cancer	8.48e-06	7.22e-05	CbGpPWpGaD
Dronedarone—ADRA1B—Signaling Pathways—PIK3CB—ovarian cancer	8.48e-06	7.22e-05	CbGpPWpGaD
Dronedarone—ADRA1B—Signaling Pathways—MTOR—ovarian cancer	8.48e-06	7.22e-05	CbGpPWpGaD
Dronedarone—ADRA2B—Signaling Pathways—IL2—ovarian cancer	8.47e-06	7.21e-05	CbGpPWpGaD
Dronedarone—CYP3A4—Metabolism—SLC5A5—ovarian cancer	8.46e-06	7.21e-05	CbGpPWpGaD
Dronedarone—ADRA1A—Signaling by GPCR—KRAS—ovarian cancer	8.46e-06	7.2e-05	CbGpPWpGaD
Dronedarone—ADRA2B—Signaling by GPCR—IL6—ovarian cancer	8.42e-06	7.18e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Metabolism—PIK3CB—ovarian cancer	8.37e-06	7.13e-05	CbGpPWpGaD
Dronedarone—ADRB1—Signaling Pathways—CCND1—ovarian cancer	8.33e-06	7.1e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling by GPCR—MAPK1—ovarian cancer	8.32e-06	7.09e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling by GPCR—EGFR—ovarian cancer	8.32e-06	7.08e-05	CbGpPWpGaD
Dronedarone—ABCB1—Metabolism—CAV1—ovarian cancer	8.29e-06	7.06e-05	CbGpPWpGaD
Dronedarone—ADRA2C—Signaling Pathways—CXCL8—ovarian cancer	8.28e-06	7.05e-05	CbGpPWpGaD
Dronedarone—ADRA2B—Signaling Pathways—CCND1—ovarian cancer	8.25e-06	7.03e-05	CbGpPWpGaD
Dronedarone—ADRB1—Signaling Pathways—CTNNB1—ovarian cancer	8.25e-06	7.03e-05	CbGpPWpGaD
Dronedarone—ADRA2C—Signaling by GPCR—HRAS—ovarian cancer	8.22e-06	7e-05	CbGpPWpGaD
Dronedarone—ADRA2B—Signaling Pathways—CTNNB1—ovarian cancer	8.17e-06	6.96e-05	CbGpPWpGaD
Dronedarone—CYP3A4—Metabolism—SLC2A1—ovarian cancer	8.17e-06	6.96e-05	CbGpPWpGaD
Dronedarone—ADRA1B—Signaling Pathways—CXCL8—ovarian cancer	8.15e-06	6.94e-05	CbGpPWpGaD
Dronedarone—ALB—Hemostasis—AKT1—ovarian cancer	8.11e-06	6.91e-05	CbGpPWpGaD
Dronedarone—ADRA1B—Signaling by GPCR—HRAS—ovarian cancer	8.09e-06	6.89e-05	CbGpPWpGaD
Dronedarone—ADRB1—Signaling Pathways—MMP9—ovarian cancer	8.09e-06	6.89e-05	CbGpPWpGaD
Dronedarone—ADRA2C—Signaling Pathways—CDKN1B—ovarian cancer	8.08e-06	6.88e-05	CbGpPWpGaD
Dronedarone—ADRB1—Signaling Pathways—PTEN—ovarian cancer	8.04e-06	6.85e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling Pathways—PIK3CD—ovarian cancer	8.03e-06	6.84e-05	CbGpPWpGaD
Dronedarone—ADRA2B—Signaling Pathways—MMP9—ovarian cancer	8.01e-06	6.83e-05	CbGpPWpGaD
Dronedarone—ADRA2C—GPCR downstream signaling—AKT1—ovarian cancer	7.99e-06	6.81e-05	CbGpPWpGaD
Dronedarone—ADRA1D—Signaling Pathways—VEGFA—ovarian cancer	7.97e-06	6.79e-05	CbGpPWpGaD
Dronedarone—ADRA2B—Signaling Pathways—PTEN—ovarian cancer	7.97e-06	6.79e-05	CbGpPWpGaD
Dronedarone—ADRA1B—Signaling Pathways—CDKN1B—ovarian cancer	7.95e-06	6.78e-05	CbGpPWpGaD
Dronedarone—ADRA2A—GPCR downstream signaling—PIK3CA—ovarian cancer	7.95e-06	6.77e-05	CbGpPWpGaD
Dronedarone—ADRA2C—Signaling Pathways—CASP3—ovarian cancer	7.92e-06	6.75e-05	CbGpPWpGaD
Dronedarone—ADRA2C—Signaling Pathways—IL2—ovarian cancer	7.91e-06	6.74e-05	CbGpPWpGaD
Dronedarone—ADRA1D—Signaling Pathways—STAT3—ovarian cancer	7.89e-06	6.72e-05	CbGpPWpGaD
Dronedarone—ADRA1D—Signaling Pathways—NRAS—ovarian cancer	7.87e-06	6.71e-05	CbGpPWpGaD
Dronedarone—ADRA2C—Signaling by GPCR—IL6—ovarian cancer	7.87e-06	6.7e-05	CbGpPWpGaD
Dronedarone—ADRA1B—GPCR downstream signaling—AKT1—ovarian cancer	7.87e-06	6.7e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling by GPCR—KRAS—ovarian cancer	7.86e-06	6.69e-05	CbGpPWpGaD
Dronedarone—ADRB1—Signaling by GPCR—AKT1—ovarian cancer	7.84e-06	6.68e-05	CbGpPWpGaD
Dronedarone—CYP3A4—Metabolism—CYP1B1—ovarian cancer	7.84e-06	6.67e-05	CbGpPWpGaD
Dronedarone—CYP2D6—Metabolism—CAV1—ovarian cancer	7.81e-06	6.65e-05	CbGpPWpGaD
Dronedarone—ADRA1B—Signaling Pathways—CASP3—ovarian cancer	7.8e-06	6.64e-05	CbGpPWpGaD
Dronedarone—ADRA1B—Signaling Pathways—IL2—ovarian cancer	7.78e-06	6.63e-05	CbGpPWpGaD
Dronedarone—ADRA2B—Signaling by GPCR—AKT1—ovarian cancer	7.77e-06	6.62e-05	CbGpPWpGaD
Dronedarone—ADRA1A—Signaling by GPCR—PIK3CA—ovarian cancer	7.77e-06	6.62e-05	CbGpPWpGaD
Dronedarone—ADRA1B—Signaling by GPCR—IL6—ovarian cancer	7.75e-06	6.6e-05	CbGpPWpGaD
Dronedarone—ADRA2C—Signaling Pathways—CCND1—ovarian cancer	7.71e-06	6.57e-05	CbGpPWpGaD
Dronedarone—ADRA2C—Signaling Pathways—CTNNB1—ovarian cancer	7.64e-06	6.5e-05	CbGpPWpGaD
Dronedarone—ADRA1A—Signaling Pathways—ERBB2—ovarian cancer	7.63e-06	6.5e-05	CbGpPWpGaD
Dronedarone—ADRA1B—Signaling Pathways—CCND1—ovarian cancer	7.59e-06	6.46e-05	CbGpPWpGaD
Dronedarone—ALB—Metabolism—PIK3CD—ovarian cancer	7.57e-06	6.45e-05	CbGpPWpGaD
Dronedarone—ABCB1—Metabolism—PIK3CG—ovarian cancer	7.55e-06	6.43e-05	CbGpPWpGaD
Dronedarone—ADRA1D—Signaling Pathways—MAPK3—ovarian cancer	7.54e-06	6.42e-05	CbGpPWpGaD
Dronedarone—ADRA1A—Signaling Pathways—MTOR—ovarian cancer	7.53e-06	6.41e-05	CbGpPWpGaD
Dronedarone—ADRA1A—Signaling Pathways—PIK3CB—ovarian cancer	7.53e-06	6.41e-05	CbGpPWpGaD
Dronedarone—ADRA1B—Signaling Pathways—CTNNB1—ovarian cancer	7.51e-06	6.4e-05	CbGpPWpGaD
Dronedarone—ADRA2C—Signaling Pathways—MMP9—ovarian cancer	7.49e-06	6.38e-05	CbGpPWpGaD
Dronedarone—ADRA2C—Signaling Pathways—PTEN—ovarian cancer	7.44e-06	6.34e-05	CbGpPWpGaD
Dronedarone—ADRA1B—Signaling Pathways—MMP9—ovarian cancer	7.37e-06	6.27e-05	CbGpPWpGaD
Dronedarone—ADRA1D—Signaling Pathways—MYC—ovarian cancer	7.33e-06	6.25e-05	CbGpPWpGaD
Dronedarone—ADRA1B—Signaling Pathways—PTEN—ovarian cancer	7.32e-06	6.24e-05	CbGpPWpGaD
Dronedarone—ADRB1—Signaling Pathways—VEGFA—ovarian cancer	7.26e-06	6.19e-05	CbGpPWpGaD
Dronedarone—ADRA2C—Signaling by GPCR—AKT1—ovarian cancer	7.26e-06	6.18e-05	CbGpPWpGaD
Dronedarone—ADRA1A—Signaling Pathways—CXCL8—ovarian cancer	7.23e-06	6.16e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Metabolism—PTEN—ovarian cancer	7.23e-06	6.16e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling by GPCR—PIK3CA—ovarian cancer	7.22e-06	6.15e-05	CbGpPWpGaD
Dronedarone—ADRA2B—Signaling Pathways—VEGFA—ovarian cancer	7.2e-06	6.13e-05	CbGpPWpGaD
Dronedarone—ADRB1—Signaling Pathways—STAT3—ovarian cancer	7.19e-06	6.12e-05	CbGpPWpGaD
Dronedarone—ADRA1A—Signaling by GPCR—HRAS—ovarian cancer	7.19e-06	6.12e-05	CbGpPWpGaD
Dronedarone—ADRA1D—Signaling Pathways—MAPK1—ovarian cancer	7.17e-06	6.11e-05	CbGpPWpGaD
Dronedarone—ADRB1—Signaling Pathways—NRAS—ovarian cancer	7.17e-06	6.11e-05	CbGpPWpGaD
Dronedarone—ADRA1D—Signaling Pathways—EGFR—ovarian cancer	7.17e-06	6.11e-05	CbGpPWpGaD
Dronedarone—ADRA1B—Signaling by GPCR—AKT1—ovarian cancer	7.15e-06	6.09e-05	CbGpPWpGaD
Dronedarone—ADRA2B—Signaling Pathways—STAT3—ovarian cancer	7.13e-06	6.07e-05	CbGpPWpGaD
Dronedarone—CYP2D6—Metabolism—PIK3CG—ovarian cancer	7.11e-06	6.06e-05	CbGpPWpGaD
Dronedarone—ADRA2B—Signaling Pathways—NRAS—ovarian cancer	7.11e-06	6.05e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling Pathways—ERBB2—ovarian cancer	7.09e-06	6.04e-05	CbGpPWpGaD
Dronedarone—ADRA1A—Signaling Pathways—CDKN1B—ovarian cancer	7.07e-06	6.02e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling Pathways—PIK3CB—ovarian cancer	7e-06	5.96e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling Pathways—MTOR—ovarian cancer	7e-06	5.96e-05	CbGpPWpGaD
Dronedarone—ADRA1A—GPCR downstream signaling—AKT1—ovarian cancer	6.99e-06	5.95e-05	CbGpPWpGaD
Dronedarone—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	6.95e-06	5.92e-05	CbGpPWpGaD
Dronedarone—ADRA1A—Signaling Pathways—CASP3—ovarian cancer	6.92e-06	5.9e-05	CbGpPWpGaD
Dronedarone—ADRA1A—Signaling Pathways—IL2—ovarian cancer	6.91e-06	5.89e-05	CbGpPWpGaD
Dronedarone—ADRA1A—Signaling by GPCR—IL6—ovarian cancer	6.88e-06	5.86e-05	CbGpPWpGaD
Dronedarone—ADRB1—Signaling Pathways—MAPK3—ovarian cancer	6.87e-06	5.85e-05	CbGpPWpGaD
Dronedarone—ADRA2B—Signaling Pathways—MAPK3—ovarian cancer	6.81e-06	5.8e-05	CbGpPWpGaD
Dronedarone—ADRA1D—Signaling Pathways—KRAS—ovarian cancer	6.78e-06	5.77e-05	CbGpPWpGaD
Dronedarone—ADRA1A—Signaling Pathways—CCND1—ovarian cancer	6.74e-06	5.74e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling Pathways—CXCL8—ovarian cancer	6.72e-06	5.73e-05	CbGpPWpGaD
Dronedarone—ADRA2C—Signaling Pathways—VEGFA—ovarian cancer	6.72e-06	5.73e-05	CbGpPWpGaD
Dronedarone—ADRB1—Signaling Pathways—MYC—ovarian cancer	6.68e-06	5.69e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling by GPCR—HRAS—ovarian cancer	6.68e-06	5.69e-05	CbGpPWpGaD
Dronedarone—ADRA1A—Signaling Pathways—CTNNB1—ovarian cancer	6.67e-06	5.69e-05	CbGpPWpGaD
Dronedarone—ADRA2C—Signaling Pathways—STAT3—ovarian cancer	6.66e-06	5.67e-05	CbGpPWpGaD
Dronedarone—ADRA2C—Signaling Pathways—NRAS—ovarian cancer	6.64e-06	5.66e-05	CbGpPWpGaD
Dronedarone—ABCB1—Metabolism—PIK3CD—ovarian cancer	6.64e-06	5.65e-05	CbGpPWpGaD
Dronedarone—ADRA2B—Signaling Pathways—MYC—ovarian cancer	6.62e-06	5.64e-05	CbGpPWpGaD
Dronedarone—ADRA1B—Signaling Pathways—VEGFA—ovarian cancer	6.62e-06	5.63e-05	CbGpPWpGaD
Dronedarone—ALB—Metabolism—PIK3CB—ovarian cancer	6.6e-06	5.62e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling Pathways—CDKN1B—ovarian cancer	6.56e-06	5.59e-05	CbGpPWpGaD
Dronedarone—ADRA1B—Signaling Pathways—STAT3—ovarian cancer	6.55e-06	5.58e-05	CbGpPWpGaD
Dronedarone—ADRA1A—Signaling Pathways—MMP9—ovarian cancer	6.54e-06	5.57e-05	CbGpPWpGaD
Dronedarone—ADRB1—Signaling Pathways—MAPK1—ovarian cancer	6.54e-06	5.57e-05	CbGpPWpGaD
Dronedarone—ADRB1—Signaling Pathways—EGFR—ovarian cancer	6.54e-06	5.57e-05	CbGpPWpGaD
Dronedarone—ADRA1B—Signaling Pathways—NRAS—ovarian cancer	6.53e-06	5.57e-05	CbGpPWpGaD
Dronedarone—ADRA1A—Signaling Pathways—PTEN—ovarian cancer	6.51e-06	5.54e-05	CbGpPWpGaD
Dronedarone—ADRA2A—GPCR downstream signaling—AKT1—ovarian cancer	6.49e-06	5.53e-05	CbGpPWpGaD
Dronedarone—ADRA2B—Signaling Pathways—MAPK1—ovarian cancer	6.48e-06	5.52e-05	CbGpPWpGaD
Dronedarone—ADRA2B—Signaling Pathways—EGFR—ovarian cancer	6.48e-06	5.52e-05	CbGpPWpGaD
Dronedarone—CYP3A4—Metabolism—ABCB1—ovarian cancer	6.45e-06	5.5e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling Pathways—CASP3—ovarian cancer	6.43e-06	5.48e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling Pathways—IL2—ovarian cancer	6.42e-06	5.47e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling by GPCR—IL6—ovarian cancer	6.39e-06	5.44e-05	CbGpPWpGaD
Dronedarone—ADRA2C—Signaling Pathways—MAPK3—ovarian cancer	6.36e-06	5.42e-05	CbGpPWpGaD
Dronedarone—ADRA1A—Signaling by GPCR—AKT1—ovarian cancer	6.35e-06	5.41e-05	CbGpPWpGaD
Dronedarone—CYP3A4—Metabolism—TYMS—ovarian cancer	6.34e-06	5.4e-05	CbGpPWpGaD
Dronedarone—ADRA2C—Metabolism—PIK3CA—ovarian cancer	6.28e-06	5.35e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling Pathways—CCND1—ovarian cancer	6.26e-06	5.33e-05	CbGpPWpGaD
Dronedarone—ADRA1B—Signaling Pathways—MAPK3—ovarian cancer	6.26e-06	5.33e-05	CbGpPWpGaD
Dronedarone—CYP2D6—Metabolism—PIK3CD—ovarian cancer	6.25e-06	5.33e-05	CbGpPWpGaD
Dronedarone—ADRA1D—Signaling Pathways—PIK3CA—ovarian cancer	6.23e-06	5.3e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling Pathways—CTNNB1—ovarian cancer	6.2e-06	5.28e-05	CbGpPWpGaD
Dronedarone—ADRA2C—Signaling Pathways—MYC—ovarian cancer	6.18e-06	5.27e-05	CbGpPWpGaD
Dronedarone—ADRB1—Signaling Pathways—KRAS—ovarian cancer	6.17e-06	5.26e-05	CbGpPWpGaD
Dronedarone—ADRA2B—Signaling Pathways—KRAS—ovarian cancer	6.12e-06	5.21e-05	CbGpPWpGaD
Dronedarone—ADRA1B—Signaling Pathways—MYC—ovarian cancer	6.09e-06	5.18e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling Pathways—MMP9—ovarian cancer	6.08e-06	5.18e-05	CbGpPWpGaD
Dronedarone—ADRA2C—Signaling Pathways—MAPK1—ovarian cancer	6.05e-06	5.15e-05	CbGpPWpGaD
Dronedarone—ADRA2C—Signaling Pathways—EGFR—ovarian cancer	6.05e-06	5.15e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling Pathways—PTEN—ovarian cancer	6.04e-06	5.15e-05	CbGpPWpGaD
Dronedarone—ADRA1D—Signaling Pathways—TP53—ovarian cancer	6.02e-06	5.13e-05	CbGpPWpGaD
Dronedarone—ADRA1B—Signaling Pathways—MAPK1—ovarian cancer	5.95e-06	5.07e-05	CbGpPWpGaD
Dronedarone—ADRA1B—Signaling Pathways—EGFR—ovarian cancer	5.95e-06	5.07e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling by GPCR—AKT1—ovarian cancer	5.9e-06	5.02e-05	CbGpPWpGaD
Dronedarone—ADRA1A—Signaling Pathways—VEGFA—ovarian cancer	5.88e-06	5e-05	CbGpPWpGaD
Dronedarone—ADRA1A—Signaling Pathways—STAT3—ovarian cancer	5.82e-06	4.96e-05	CbGpPWpGaD
Dronedarone—ADRA1A—Signaling Pathways—NRAS—ovarian cancer	5.8e-06	4.94e-05	CbGpPWpGaD
Dronedarone—ABCB1—Metabolism—PIK3CB—ovarian cancer	5.78e-06	4.93e-05	CbGpPWpGaD
Dronedarone—ADRA1D—Signaling Pathways—HRAS—ovarian cancer	5.76e-06	4.91e-05	CbGpPWpGaD
Dronedarone—ADRA2C—Signaling Pathways—KRAS—ovarian cancer	5.71e-06	4.87e-05	CbGpPWpGaD
Dronedarone—ALB—Metabolism—PTEN—ovarian cancer	5.71e-06	4.86e-05	CbGpPWpGaD
Dronedarone—ADRB1—Signaling Pathways—PIK3CA—ovarian cancer	5.67e-06	4.83e-05	CbGpPWpGaD
Dronedarone—ADRA1B—Signaling Pathways—KRAS—ovarian cancer	5.62e-06	4.79e-05	CbGpPWpGaD
Dronedarone—ADRA2B—Signaling Pathways—PIK3CA—ovarian cancer	5.62e-06	4.79e-05	CbGpPWpGaD
Dronedarone—ADRA1A—Signaling Pathways—MAPK3—ovarian cancer	5.56e-06	4.73e-05	CbGpPWpGaD
Dronedarone—ADRA1D—Signaling Pathways—IL6—ovarian cancer	5.51e-06	4.7e-05	CbGpPWpGaD
Dronedarone—ADRB1—Signaling Pathways—TP53—ovarian cancer	5.49e-06	4.67e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling Pathways—VEGFA—ovarian cancer	5.46e-06	4.65e-05	CbGpPWpGaD
Dronedarone—CYP2D6—Metabolism—PIK3CB—ovarian cancer	5.45e-06	4.64e-05	CbGpPWpGaD
Dronedarone—ADRA2B—Signaling Pathways—TP53—ovarian cancer	5.44e-06	4.63e-05	CbGpPWpGaD
Dronedarone—ADRA1A—Signaling Pathways—MYC—ovarian cancer	5.41e-06	4.6e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling Pathways—STAT3—ovarian cancer	5.41e-06	4.6e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling Pathways—NRAS—ovarian cancer	5.39e-06	4.59e-05	CbGpPWpGaD
Dronedarone—ADRA1A—Signaling Pathways—MAPK1—ovarian cancer	5.29e-06	4.5e-05	CbGpPWpGaD
Dronedarone—ADRA1A—Signaling Pathways—EGFR—ovarian cancer	5.29e-06	4.5e-05	CbGpPWpGaD
Dronedarone—ADRA2C—Signaling Pathways—PIK3CA—ovarian cancer	5.25e-06	4.47e-05	CbGpPWpGaD
Dronedarone—ADRB1—Signaling Pathways—HRAS—ovarian cancer	5.25e-06	4.47e-05	CbGpPWpGaD
Dronedarone—ADRA2B—Signaling Pathways—HRAS—ovarian cancer	5.2e-06	4.43e-05	CbGpPWpGaD
Dronedarone—ADRA1B—Signaling Pathways—PIK3CA—ovarian cancer	5.17e-06	4.4e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling Pathways—MAPK3—ovarian cancer	5.16e-06	4.4e-05	CbGpPWpGaD
Dronedarone—ADRA2C—Metabolism—AKT1—ovarian cancer	5.13e-06	4.37e-05	CbGpPWpGaD
Dronedarone—CYP3A4—Metabolism—CAV1—ovarian cancer	5.11e-06	4.35e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Metabolism—PIK3CA—ovarian cancer	5.1e-06	4.34e-05	CbGpPWpGaD
Dronedarone—ADRA1D—Signaling Pathways—AKT1—ovarian cancer	5.09e-06	4.33e-05	CbGpPWpGaD
Dronedarone—ADRA2C—Signaling Pathways—TP53—ovarian cancer	5.08e-06	4.33e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling Pathways—MYC—ovarian cancer	5.02e-06	4.28e-05	CbGpPWpGaD
Dronedarone—ADRB1—Signaling Pathways—IL6—ovarian cancer	5.02e-06	4.28e-05	CbGpPWpGaD
Dronedarone—ABCB1—Metabolism—PTEN—ovarian cancer	5e-06	4.26e-05	CbGpPWpGaD
Dronedarone—ADRA1B—Signaling Pathways—TP53—ovarian cancer	5e-06	4.26e-05	CbGpPWpGaD
Dronedarone—ADRA1A—Signaling Pathways—KRAS—ovarian cancer	5e-06	4.25e-05	CbGpPWpGaD
Dronedarone—ADRA2B—Signaling Pathways—IL6—ovarian cancer	4.98e-06	4.24e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling Pathways—MAPK1—ovarian cancer	4.91e-06	4.19e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling Pathways—EGFR—ovarian cancer	4.91e-06	4.18e-05	CbGpPWpGaD
Dronedarone—ADRA2C—Signaling Pathways—HRAS—ovarian cancer	4.86e-06	4.14e-05	CbGpPWpGaD
Dronedarone—ADRA1B—Signaling Pathways—HRAS—ovarian cancer	4.78e-06	4.07e-05	CbGpPWpGaD
Dronedarone—CYP2D6—Metabolism—PTEN—ovarian cancer	4.71e-06	4.01e-05	CbGpPWpGaD
Dronedarone—CYP3A4—Metabolism—PIK3CG—ovarian cancer	4.65e-06	3.96e-05	CbGpPWpGaD
Dronedarone—ADRA2C—Signaling Pathways—IL6—ovarian cancer	4.65e-06	3.96e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling Pathways—KRAS—ovarian cancer	4.64e-06	3.95e-05	CbGpPWpGaD
Dronedarone—ADRB1—Signaling Pathways—AKT1—ovarian cancer	4.63e-06	3.95e-05	CbGpPWpGaD
Dronedarone—ADRA2B—Signaling Pathways—AKT1—ovarian cancer	4.59e-06	3.91e-05	CbGpPWpGaD
Dronedarone—ADRA1A—Signaling Pathways—PIK3CA—ovarian cancer	4.59e-06	3.91e-05	CbGpPWpGaD
Dronedarone—ADRA1B—Signaling Pathways—IL6—ovarian cancer	4.58e-06	3.9e-05	CbGpPWpGaD
Dronedarone—ADRA1A—Signaling Pathways—TP53—ovarian cancer	4.44e-06	3.78e-05	CbGpPWpGaD
Dronedarone—ADRA2C—Signaling Pathways—AKT1—ovarian cancer	4.29e-06	3.65e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling Pathways—PIK3CA—ovarian cancer	4.26e-06	3.63e-05	CbGpPWpGaD
Dronedarone—ADRA1A—Signaling Pathways—HRAS—ovarian cancer	4.25e-06	3.62e-05	CbGpPWpGaD
Dronedarone—ADRA1B—Signaling Pathways—AKT1—ovarian cancer	4.22e-06	3.6e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Metabolism—AKT1—ovarian cancer	4.17e-06	3.55e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling Pathways—TP53—ovarian cancer	4.13e-06	3.51e-05	CbGpPWpGaD
Dronedarone—CYP3A4—Metabolism—PIK3CD—ovarian cancer	4.09e-06	3.48e-05	CbGpPWpGaD
Dronedarone—ADRA1A—Signaling Pathways—IL6—ovarian cancer	4.06e-06	3.46e-05	CbGpPWpGaD
Dronedarone—ALB—Metabolism—PIK3CA—ovarian cancer	4.02e-06	3.43e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling Pathways—HRAS—ovarian cancer	3.95e-06	3.36e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling Pathways—IL6—ovarian cancer	3.78e-06	3.22e-05	CbGpPWpGaD
Dronedarone—ADRA1A—Signaling Pathways—AKT1—ovarian cancer	3.75e-06	3.19e-05	CbGpPWpGaD
Dronedarone—CYP3A4—Metabolism—PIK3CB—ovarian cancer	3.56e-06	3.04e-05	CbGpPWpGaD
Dronedarone—ABCB1—Metabolism—PIK3CA—ovarian cancer	3.53e-06	3e-05	CbGpPWpGaD
Dronedarone—ADRA2A—Signaling Pathways—AKT1—ovarian cancer	3.48e-06	2.97e-05	CbGpPWpGaD
Dronedarone—CYP2D6—Metabolism—PIK3CA—ovarian cancer	3.32e-06	2.83e-05	CbGpPWpGaD
Dronedarone—ALB—Metabolism—AKT1—ovarian cancer	3.29e-06	2.8e-05	CbGpPWpGaD
Dronedarone—CYP3A4—Metabolism—PTEN—ovarian cancer	3.08e-06	2.62e-05	CbGpPWpGaD
Dronedarone—ABCB1—Metabolism—AKT1—ovarian cancer	2.88e-06	2.45e-05	CbGpPWpGaD
Dronedarone—CYP2D6—Metabolism—AKT1—ovarian cancer	2.71e-06	2.31e-05	CbGpPWpGaD
Dronedarone—CYP3A4—Metabolism—PIK3CA—ovarian cancer	2.17e-06	1.85e-05	CbGpPWpGaD
Dronedarone—CYP3A4—Metabolism—AKT1—ovarian cancer	1.77e-06	1.51e-05	CbGpPWpGaD
